Interleukin 10 (IL-10) stimulates rapid nuclear translocation and binding of a 22 kDa protein, termed interleukin 10 enhancer 1 (IL-10E1), to a novel enhancer element (i.e. HTE-1) of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene to upregulate TIMP-1 expression. IL-10E1 signaling involves tyrosine phosphorylation of the IL-10R JAK1 (Janus kinase) and TYK2 (tyrosine kinase) receptor kinases and tyrosine phosphorylation of two tyrosine moieties (Y57 and Y62) of a LIM domain of the IL-10E1 protein. In this paper, the studies showed that two tyrosine residues (Tyr 446 and Tyr
Interleukin 10 (IL-10) stimulates rapid nuclear translocation and binding of a 22 kDa protein, termed interleukin 10 enhancer 1 (IL-10E1), to a novel enhancer element (i.e. HTE-1) of the tissue inhibitor of metalloproteinase-1 (TIMP-1) gene to upregulate TIMP-1 expression. IL-10E1 signaling involves tyrosine phosphorylation of the IL-10R JAK1 (Janus kinase) and TYK2 (tyrosine kinase) receptor kinases and tyrosine phosphorylation of two tyrosine moieties (Y57 and Y62) of a LIM domain of the IL-10E1 protein. In this paper, the studies showed that two tyrosine residues (Tyr  446 and Tyr   496 ) located in the cytoplasmic domain of the IL-10R a chain were required for receptor function, and for phosphorylation and activation of IL-10E1. Immunoprecipitation studies revealed that 12 amino-acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated IL-10E1 and blocked ligand-dependent IL-10E1 phosphorylation in a cell-free system. In contrast, peptides containing serine substitutions for Tyr 446 and Tyr
496
, and tyrosine-phosphorylated peptides containing Tyr 230 or Tyr 252/259 did not prevent IL-10E1 activation or signaling. To confirm these observations in vivo, fusion protein constructs were made between a modified form of green fluorescent protein or GFP and the intact IL-10E1 protein (IL-10E1-MmGFP) and n-terminal peptides of the IL-10E1 protein (i.e. nt-nls-MmGFP and mutant sequences identified as nt-nls mC61-MmGFP and nt-nls mY57/mY62-MmGFP peptides). Confocal microscopy revealed that IL-10 triggered transport to the nucleus of IL-10E1-MmGFP, nt-nls-MmGFP, and ntnls mC61-MmGFP by 10-30 min in HPCA-10a (human prostrate cancer cells; derived from Gleason sum 10 tumor tissue) cells. IL-10 failed to induce nuclear translocation of the mY57/mY62-MmGFP peptides with point mutations of the two tyrosine groups. Coinjection of nt-nlsMmGFP with the IL-10R Tyr 446 and Tyr 496 amino-acid residues completely blocked ligand signaling. Coinjection of peptides containing either serine substitutions for Tyr Introduction Interleukin-10 (IL-10) is a cytokine produced by Th0 and Th2 CD4 þ T cells, CD5 þ B cells, and macrophages Howard and O'Garra, 1992; Oswald et al., 1993) that inhibits inflammatory and cellmediated immune responses while enhancing humoral immunity (O'Garra et al., 1990; Mosmann, 1991; Darnell et al., 1994) . IL-10 exerts its effects following interaction with the interleukin 10 receptor (IL-10R) , and binds to its receptor in a homogeneous manner with high affinity. The cDNA encoding the ligand-binding polypeptide of the IL-10R was cloned, and the receptor polypeptide identified as a 110-kDa glycoprotein . Based on sequence homology, this protein has been characterized as a member of the type II cytokine receptor family that also contains the IFNa and IFNg receptor polypeptides. Receptor proteins belonging to the type I and type II cytokine receptor families have been found to utilize the JAK-STAT (Janus kinase-signal transducer and activator of transduction) family of proteins for signal transduction in white blood cells (Miyajima et al., 1992; Shuai et al., 1992; Fu and Zhang, 1993; Kotanides and Reich, 1993; Sadowski et al., 1993; Hou et al., 1994; Zhong et al., 1994; Greenlund et al., 1995) . Currently, this family consists of four Janus family tyrosine kinases (JAK-1, JAK-2, JAK-3, and tyrosine kinase (TYK)-2) and seven latent cytosolic transcription factors (interleukin 10 enhancer 1 (IL-10E1)-Stat6). Recent work has indicated that each cytokine receptor uses a distinct but often overlapping combination of JAKs and STATs to effect development of cytokine-specific cellular responses. The specificity of the signal transduction pathway appears to be determined by the recruitment of particular STAT proteins to the activated receptor.
Schrieber and co-workers pioneered early studies into the mechanism underlying STAT recruitment by cytokine receptors (Greenlund et al., 1995) . That work revealed that IFNg-IFNg receptor interaction leads to the rapid phosphorylation of a tyrosine within the pentameric sequence YDKPH in the cytoplasmic domain of the human and murine IFNg receptor a chains (residues 440-444 and 420-424) in the human and murine proteins, respectively (Greenlund et al., 1995) . This sequence thus appears to act as the IFNg receptor docking site for STAT1 but not for any other STAT family member (Greenlund et al., 1995) . This concept was supported by subsequent work showing that the specific array of STAT proteins recruited by ligated cytokine receptors can be altered either by adding sequences from other receptors that recruit different STAT proteins (Heim et al., 1995; Stahl et al., 1995) or by exchanging the SH2 domains of one STAT for another (Stahl et al., 1995) . Similar studies of the IL-10R revealed that IL-10 activates STAT1, Stat3, and STAT5 signaling depending on the white blood cell type (Larner et al., 1993) . For example, a pair of tyrosine residues residing at positions 446 and 496 within the cytoplasmic domain of the murine IL-10R were required for Stat3 recruitment, but not for STAT1 or STAT5 recruitment and for induction of an IL-10-dependent biologic response (Larner et al., 1993) . The results strongly indicated that IL-10 and the IL-10R effect multiple STAT protein recruitment and signaling events. Recruitment is dependent on the specificity of the Src homology 2 (SH2) domain in the STAT protein for a particular phosphotyrosine-containing sequence motif within the cytoplasmic domain of the cytokine receptor.
We originally reported that IL-10 signaling stimulated activation of a specific enhancer element, termed HTE-1, to promote tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) expression in human prostate PC-3 ML cells (Wang et al., 1998) . Recently, we have identified IL-10E1 as one of the signal molecules that binds the HTE enhancer element to activate TIMP-1 expression in human prostate cancer cells (HPCA) (Liu et al., 1993) . IL-10 binding to the IL-10R was found to induce tyrosine phosphorylation of the JAK-1/TYK2 kinases, tyrosine phosphorylation of Y57 and Y62 tyrosines in the 'n-terminal' domain of the IL-10E1 protein and the rapid transport to the nucleus of the IL-10E1 protein (Liu et al., 1993) . Immunoprecipitation assays showed that phosphorylation of mY57/mY62 tyrosines triggered redistribution of the intact IL-10E1 protein and the n-terminal peptide of IL-10E1 (nt-nls) fragment in both normal and malignant human prostate cell lines. The nt-nls mY57/mY62 fragments containing mutated tyrosines were not phosphorylated following IL-10 treatment of transfected cells and the nt-nls peptide failed to migrate to the nucleus in these cells. In addition, nuclear translocation of the nt-nls fragment (and presumably the intact IL-10E1 protein as well) required the nuclear localization signal (nls), but not the remaining c-terminal domain of the IL-10E1 protein (Liu et al., 1993) . These data indicate that the mechanism of activation of the LIM domain (i.e. the nls region) of IL-10E1 may involve changes in proteinprotein interaction, or perhaps conformational changes in the IL-10E1 protein mediated by tyrosine phosphorylation of LIM domain Y57 and Y62 groups (Liu et al., 1993) . The data also confirmed that the n-terminal domain, and specifically the region spanning about 17 amino acids (e.g. YCKSCYGKKYGPKGYGY) of the LIM domain were primarily responsible for nuclear translocation of the IL-10E1 protein (Liu et al., 1993) . We believe therefore that this domain may also control binding to the HTE-1 element and activation of TIMP-1 expression (Wang et al., 2002) .
In this paper, we have extended these preliminary studies to examine the mechanism underlying signal transduction activation of transcription protein recruitment to the IL-10R. The data demonstrate, for the first time, that two tyrosine residues (Tyr 446 and Tyr 496 ) located in the cytoplasmic domain of the IL-10R play a key role in mediating tyrosine phosphorylation of Y57/ Y62 groups of the LIM domain of the IL-10E1 protein to enable IL-10E1 activation and translocation to the nucleus.
Materials and methods

Cell cultures
The HPCA-10a, HPCA-10b, HPCA-10c, and HPCA-10d cell strains were isolated from Gleason score 10 prostate glands and maintained in culture at low passage (o5 passages) (Wang et al., 1996) . These epithelial cells and HPV-18 immortalized strains derived from the HPCA-10a and HPCA-10c strains have been previously characterized and found to express PSA and cytokeratins 8 and 18 (Wang et al., 1996) . Cultures were immortalized and maintained in MGEM medium supplemented with pituitary extract and 0.1% ITS according to Clonetics (San Diego, CA, USA). according to published methods (Peehl et al., 1994; Rhim et al., 1994 ; Bright et al., 1997) . Unless otherwise stated, the cells were treated with IL-10 at 15 ng/ml. The different cell strains were transferred to fresh medium containing 10 nm DHT and 10 mm HEPES buffer, but without supplements (i.e. pituitary extracts and ITS) for 30 min prior to carrying out the IL-10 studies.
Electrophoretic mobility shift assay (EMSA)
Cells in culture B5 Â 10 7 cells/T175 flask were washed with serum-free medium 2X and then stimulated with either PBS or 15 ng/ml of IL-10 in a total volume of 5 ml. Cells were harvested after various periods of time, and nuclear or cytoplasmic extracts were prepared as described previously (Liu et al., 1993) . In brief, cells were removed from the plates either by gentle scraping or washing, washed in ice-cold PBS, and resuspended in 1 ml of cell lysis buffer consisting of 10 mm HEPES, pH 7.9, containing 10 mm KCl, 0.1 mm EDTA, 0.1 mm EGTA, 1 mm dithiothreitol, 0.5 mm phenylmethylsulfonyl fluoride, 25 mm NaF, 10 mg/ml each of leupeptin and aprotinin, and 0.05% Nonidet P-40. After 30 min at 41C, nuclei were pelleted by centrifugation at 1000 g for 5 min at 41C, and nuclear proteins were extracted by incubation for 30 min at 41C with 50 ml of nuclear extraction buffer (20 mm HEPES, pH 7.9, containing 0.4 M NaCl, 1 mm EDTA, 1 mm EGTA, 25% glycerol, 1 mm dithiothreitol, 0.5 mm phenylmethylsulfonyl fluoride, and 10 mg/ml each of leupeptin and aprotinin). Nuclear membranes were then pelleted for 5 min at 10 000 g, and protein concentrations of the nuclear extracts were determined using the Bradford assay (Bradford, 1976) .
Preparations were incubated with the radiolabeled HTE-1 probe (B100 000 cpm or 1 ng) for 10 min and electrophoresed by SDS-PAGE (polyacrylamide gel electrophoresis) (8% gels). Gels were dried and visualized by autoradiography using Kodak XR5 film (Eastman Kodak Co., Rochester, NY, USA). To determine the identity of transcription factors present in the DNA binding complexes, 'antibody super-shift' experiments were performed using IL-10E1-specific antisera (Liu et al., 1993) at serial dilutions of the antibody.
Site-directed mutagenesis
Site-directed mutagenesis and deletion analysis of the IL-10E1 gene was carried out according to the methods described by Sambrook et al. (1989) and by our lab in the preceding publication (Liu et al., 1993) . The deleted or mutated fragments were generated from the IL-10E1 cDNA using specific primers and PCR (B35 cycles amplification) (Liu et al., 1993) . The fragments were then subcloned and sequenced (DNA Sequencing Facility, University of Pennsylvania, Philadelphia, PA, USA) to confirm the specific deletions and mutations (Liu et al., 1993) .
Subcloning the IL-10E1 fragments
To generate the different IL-10E1 subclones, ZAP-cDNA synthesis, ligation of the ZAP-cDNA into the Uni-ZAP XR vector arms, and packaging of recombinant phage DNA were performed using a lambda phage vector-ZAP Express cDNA vector and protocol of the ZAP-cDNA Gigapack R II Gold Cloning Kit (Stratagene Inc., San Diego, CA, USA) as described in the preceding paper (Liu et al., 1993) . The cDNA fragments cloned encoded for the following peptide fragments (B8.4 kDa) of the IL-10E1 gene, including:
nt-nls:
IL-10R peptides
The following 12 amino-acid length peptides, based on the human IL-10R sequence (Accession number XM006447.8), were used in these studies, including . Peptides were synthesized on an Applied Biosystems model 432A peptide synthesizer (BioSource, Camarillo, CA, USA) with or without the addition of an amino-terminal biotin group using the biotin-amidocaproate N-hydroxysuccinimide ester. Phosphotyrosine-containing biotinylated and nonbiotinylated peptides were synthesized using FMOC (N-(9-fluorenyl)-methoxycarbonyl)-phosphorylated tyrosine by BioSource Inc. Peptides were deprotected and purified by reversed-phase highperformance liquid chromatography. The composition of the peptides was confirmed by mass spectrometry. A single moiety was detected displaying the appropriate molecular mass for each peptide. Amino-acid composition and peptide concentrations were determined using a Beckman 6300 amino-acid analyzer (Beckman Instruments).
Use of biotinylated wild-type or phosphorylated IL-10R peptides
In all, 100 ml of Streptavidin-Sepharose was incubated for 30 min at 41C with a final concentration of 100 mm phosphorylated or nonphosphorylated biotinylated peptides in a final volume of 500 ml. Beads were pelleted by centrifugation (1000 g for 5 min) and washed once with 800 ml of PBS. A total of 50 million unstimulated cells were lysed in 1 ml of 20 mm HEPESbuffered physiologic saline, pH 7.4, containing 0.5% Nonidet P-40, 5% glycerol, 1 mm EDTA, 1 mm sodium orthovanadate, 10 mm NaF, 750 mm dithiothreitol, 1 mm phenylmethylsulfonyl fluoride, and 10 mg/ml each of leupeptin and aprotinin for 30 min at 41C, and protein concentration was determined by the methods of Bradford (1976) . The protein concentration of the lysate was adjusted to 1 mg/ml, and 2 ml of the lysate was incubated for 2 h at 41C with each of the peptide-Sepharose conjugates with constant mixing. The Sepharose was pelleted and washed five times; then the proteins contained in the precipitates were analysed for the presence of IL-10E1 by SDS-PAGE (Sambrook et al., 1989) and Western blotting (Towbin et al., 1979) .
IL-10-dependent IL-10E1 protein phosphorylation in a cell-free system
Cells (5 Â 10 7 ) were resuspended in 2 ml of reaction buffer (10 mm HEPES, pH 7.5, containing 100 mm NaCl, 20 mm MgCl 2 , 200 mm ascorbic acid, 4 mm ATP, 2 mm EGTA, 1 mm phenylmethylsulfonyl fluoride, and 10 mg/ml each of leupeptin and aprotinin) and disrupted in a steel Dounce (David and Larner, 1992) . The extent of cell disruption was monitored by trypan blue exclusion. Homogenates were diluted to a protein concentration of 40 mg/ml in reaction buffer, and 450 ml (18 mg total protein) was incubated in the absence or presence of 100 mm phosphorylated or nonphosphorylated peptides for 45 min at 41C. Subsequently, the homogenates were treated for 15 min at 371C with 50 ng/ml of IL-10. The reaction was stopped by the addition of 1.5 ml of lysis buffer. Nuclei were removed by centrifugation at 10 000 g for 10 min, and lysates were precleared by incubation with 4 ml of normal goat serum and 80 ml of protein A-Sepharose. IL-10E1 proteins were precipitated using 1 ml of IL-10E1-specific antiserum and 100 ml of protein A-Sepharose. Immunoprecipitates were washed five times and analysed by SDS-PAGE and Western blotting using the phosphotyrosine-specific PY20 mAb. To control for protein loading, membranes were stripped according to the ECL protocol and then reprobed with IL-10E1 antisera.
Construction of chimeras and point mutations
IL-10E1-MmGFP fusion proteins and peptides with point mutants were constructed by PCR (35 cycles) using specific primers for the 5 0 end of the IL-10E1 gene, including: 5 0 -ATGGCAGGAGCTTCCACCGCTGCTG-3 0 and 5 0 -TACC-GTCCTCGAAGGTGGCGACGAC-3 0 . The fusion proteins were then cloned into Baculovirus or bacterial expression vectors, and sequenced on an automated sequencer (Applied Biosystems). The stop codon of IL-10E1 in the pCMX vector was mutated to an MfeI site to link IL-10E1 to MmGFP. IL-10E1 protein, nt-nls, nt-nls mC61, or nt-nls mY57/mY62 peptides fused to the second amino-acid residue of MmGFP by a 5 amino-acid linker (AGAQF) were tagged with His 6 at the N terminus and cloned into pVL1393 (Invitrogen) for expression in Baculovirus. The cDNAs for the fusion proteins were cloned into the pRSETB vector (Invitrogen) to generate an in-frame His 6 tag at the N terminus and expressed in BL21 DE3 (pLysS) bacteria.
Protein expression and purification
Full-length IL-10E1-MmGFP fusion protein, nt-nls-MmGFP, nt-nls mC61-MmGFP, and nt-nls mY57/m62-MmGFP fusion peptides were expressed in Baculovirus-infected Sf9 cells and purified on Ni-agarose followed by gel filtration and ion exchange chromatography as described by Krude et al. (1997) . The proteins were purified from batch cultures as described previously (Pines and Hunter, 1991; Siemering et al., 1996) . Proteins were dialysed overnight against PBS in a Slide-a-lyzer 10 K dialysis cassette (Pierce), concentrated in a 5000 MW cutoff microconcentrator (Qiagen). Proteins and peptides were 490% pure on silver-stained SDS-PAGE gels. Western blots with IL-10E1 or phosphotyrosine-specific PY20 antibodies were carried out on SDS-PAGE gels (Towbin et al., 1979) . The protein was microinjected into at least 300 HPCA-10a cells per experiment during a 2 h interval using an Eppendorf semiautomatic microinjector attached to a Leica DMIRBE microscope.
Confocal imaging
HPCA-10a cells were seeded onto metasilicate-coated coverslips. Cells were microinjected with either the pCMX/IL-10E1-MmGFP construct (0.1 mg/ml), the pCMX/nt-nls-MmGFP, nt-nls mC61-MmGFP, or pCMX/nt-nls mY57/mY62-MmGFP construct. At 4-6 h after injection, cells were untreated or treated for 10 or 30 min with IL-10, IFNa, IL-4, or IL-6 at 15 ng/ml. Cells were subsequently fixed in À201C methanol for 12 min and mounted onto slides. Injected cells were located, and analysed by confocal microscopy using 1% laser power and a Bio-Rad MRC 1024 confocal system on an upright Nikon fluorescence microscope equipped with a Â 40 objective. Stacks of images were exported to Adobe Photoshop and printed on a dye-sublimation printer (Tektronix, USA).
Immunolabeling studies
For some immunolabeling studies, cells were fixed in À201C methanol for 12 min and labeled with affinity-purified anti-IL-10E1 antisera (1 : 200 dilution) and then with peroxidase antiperoxidase-conjugated goat anti-rabbit secondary antibody (1 : 200 dilution). (Santa Cruz Antibodies).
Reagents IL-10 antibodies (courtesy of Dr S Narula, Schering-Plough, Kennilworth, NJ, USA); IL-10 receptor antibodies were provided courtesy of Kevin Moore (DNAX Corp., San Diego, CA, Liu et al., 1993) . Purified recombinant human IL-10 (specific activity, 1.8 Â 10 7 U/mg) was generously provided by Schering Plough (Dr S Narula, Schering-Plough, Kennilworth, NJ, USA). Protein G-Sepharose was purchased from Pharmacia Biotech Inc. Horseradish peroxidase-conjugated goat antisera specific for rabbit IgG was purchased from US Biochemical Corp. Horseradish peroxidase-conjugated antiphosphotyrosine mAb PY20 was purchased from Transduction Laboratories (Lexington, KY, USA). Rabbit polyclonal antisera specific for the n-terminal regions of IL-10E1 protein was generated in our lab and was previously characterized (Liu et al., 1993) .
Results
IL-10 stimulates IL-10E1 signaling in primary prostate tumor lines
We have previously shown that IL-10 treatment of PC-3 ML and NPTX-1532 cells activated IL-10E1 translocation to the nucleus and binding to the HTE-1 enhancer of the TIMP-1 promoter (Liu et al., 1993) . To determine whether primary prostate cancer cells exhibited similar properties, HPCA-10a, HPCA-10b, HPCA-10c, and HPCA-10d cell strains (passage 5) were treated with IL-10 (15 ng/ml for 10 min) and nuclear protein extracts isolated for binding studies with the radiolabeled HTE-1 probe. EMSAs consistently showed that the nuclear extracts from these four cell strains contained a protein that binds the HTE-1 probe (Figure 1, lanes 1-4,  respectively, arrowhead) . A 'band shift' was not observed with the nuclear extracts derived from unstimulated HPCA-10a and HPCA-10b cells (data not shown). Cold competition assays with excess cold HTE-1 oligonucleotide (10 ng) blocked binding to the radiolabeled HTE-1 probe (Figure 1, lanes 5-8) .
Competition with a random oligonucleotide sequence failed to block binding of a protein from nuclear extracts of HPCA-10a and HPCA-10c cells (Figure 1 , lanes 9-10), indicating that binding was specific. (Wang et al., 2002) . DNA-protein complexes (band-shifts, arrowhead) were separated on a 8% polyacrylamide gel and subjected to autoradiography IL-10 signaling via IL-10E1 is dependent on tyrosine phosphorylation ME Stearns et al 2-5), but at antibody dilutions of 1 : 100, the DNAprotein complex was 'super-shifted' (i.e. disappeared) (Figure 2 , lane 6), indicating that IL-10E1 was associated with the DNA-protein complexes. Control experiments revealed that no band-shift was observed with nuclear protein extracts from cells treated with PBS and only the radiolabeled probe was observed at the bottom of the gel (Figure 1, lane 1) . EMSAs also showed that the exposure of the cells to IL-10 in the presence of IL-10R antibodies blocked the formation of 'DNAprotein' complexes (i.e. 'band-shifts') with nuclear extracts from HPCA-10a, HPCA-10b, HPCA-10c, and HPCA-10d cells (Figure 2, lanes 7-10) . Likewise, excess cold HTE-1 oligonucleotide (at 10 ng) completely blocked binding of the IL-10E1 protein to radiolabeled probe in experiments with nuclear protein extracts from IL-10 treated HPCA-10a, HPCA-10b, HPCA-10c, and HPCA-10d cells (Figure 2, lanes 11-14) . Taken together, the data indicate that IL-10 induces activation of IL-10E1 in all four distinct human prostate cancer primary HPCA-10a-d cell strains expressing functionally active IL-10Rs.
Immunoprecipitation assays show IL-10E1 binding to specific IL-10R tyrosine residues
We next investigated whether IL-10E1 was recruited to the IL-10R in a manner analogous to that used in IFNg through interaction of specific STAT proteins with a specific phosphotyrosine-containing sequence within the cytoplasmic domain of the receptor. (Figure 3a, lanes 1-2) . The specificity of the interaction was confirmed by the observation that IL-10E1 was not precipitated by biotinylated forms of: (a) , and (lanes 9-10) phosphorylated Tyr 252/259 at 10 and 20 mm. Biotinylated peptides were precipitated from the incubation mixture using Streptavidin-Sepharose, washed, and subjected to Western blot analyses IL-10 signaling via IL-10E1 is dependent on tyrosine phosphorylation ME Stearns et al should inhibit the ligand-dependent activation of IL-10E1. This possibility was tested in a cell-free IL-10E1 activation assay in which cell homogenates were pretreated with IL-10R peptides and then stimulated with purified IL-10. IL-10E1 activation was assessed by immunoprecipitation and phosphotyrosine-specific Western blot analyses (Figure 4a ).
The addition of IL-10 to the homogenates of HPCA10a cells resulted in the generation of tyrosine-phosphorylated IL-10E1, which was immunoprecipitated with IL-10E1 antibodies and Western blotted with phosphotyrosine antibodies (i.e. PY20 mAb). In the absence of ligand (i.e. IL-10), little or no phosphorylated IL-10E1 was immunoprecipitated from the homogenates of the HPCA-10a cell lines. In the presence of phosphorylated IL-10R peptides (i.e. the 227-238 (230-P) peptide (Figure 4a, lanes 1-2) (Figure 4a, lanes 9-10) . To ensure that protein loading was not different among samples, the blots were stripped and reprobed with IL-10E1 antibodies. The Western blots showed that equivalent amounts of IL-10E1 were expressed in the cell lysates from the different experiments (Figure 4b,  lanes 1-10) .
Dose-response inhibition experiments were then performed to further investigate whether potential differences in potency might distinguish the Tyr
-and Tyr
496
-containing phosphopeptides (Figure 5a , b, respectively). Western blots with PY20 antibodies of IL-10E1 immunoprecipitates (top panels) from the HPCA10a cell homogenates showed that both receptor peptides were equivalent in activity. That is, both peptides partially or completely blocked IL-10E1 phosphorylation at concentrations of 20, 15, 10, and 5 mm (Figure 5a, b, lanes 1-4, respectively) . Both failed to significantly block IL-10E1 phosphorylation by the native IL-10R at lower concentrations of 2, 1, and 0.5 mm, respectively (Figure 5a , b, lanes 5-7, respectively). The blots were stripped and reblotted with IL-10E1 antibodies to confirm equivalent loading of the samples (Figure 5a , b, bottom panels).
Confocal microscopy studies show that the IL-10/IL-10R axis activates IL-10E1 signaling Confocal microscopy was employed to further evaluate whether the IL-10/IL-10R axis specifically activated IL-10E1 signaling. For these purposes, IL-10E1-MmGFP fusion protein, and fusion constructs with truncated nterminal regions of the IL-10E1 protein (i.e. nt-nlsMmGFP fusion peptide, nt-nls mC61-MmGFP fusion peptides, and nt-nls mY57/mY62-MmGFP fusion peptides) were made. Western blots with IL-10E1 antibodies confirmed that each of the GFP fusion protein/peptide constructs were 495% purified (data not shown).
HPCA-10a cells were microinjected with either IL-10E1-MmGFP fusion protein, nt-nls-MmGFP, nt-nls mC61-MmGFP, or nt-nls mY57/mY62-MmGFP fusion peptide. Following B4-5 h incubations, the cells were exposed to IL-10 for 10-30 min and then fixed with À201C methanol for confocal imaging. In untreated cells, confocal microscopy uniformly showed that IL-10E1-MmGFP fusion protein, nt-nls-MmGFP, nt-nls mC61-MmGFP, or nt-nls mY57/mY62-MmGFP fusion peptides were localized in the cytoplasmic compartment (Figure 6a, d, g, j, respectively) . Following exposure to IL-10 for 10 min, the IL-10E1-MmGFP fusion protein (496) at 100 mm. Incubation was performed for 45 min at 41C, and lysates were subsequently stimulated with 50 ng/ml recombinant human IL-10 for 15 min at 371C. After stimulation, homogenates were solubilized and cleared by centrifugation. IL-10E1 was then precipitated using specific immune rabbit serum and protein ASepharose (a). Immunoprecipitates were subjected to SDS-PAGE and phosphotyrosine-specific Western blotting using the PY20 -mAb. (b), lanes 1-10. The membranes were stripped and blotted for IL-10E1 IL-10 signaling via IL-10E1 is dependent on tyrosine phosphorylation ME Stearns et al (data not shown), nt-nls-MmGFP, and nt-nls mC61-MmGFP fusion peptides (Figure 6e , h, respectively) were localized in the nuclear compartment. Following exposure to IL-10 for 30 min, IL-10E1-MmGFP fusion protein, nt-nls-MmGFP, and nt-nls mC61-MmGFP fusion peptides were transported to the nuclear compartment (Figure 6b , f, and i, respectively). Immunoperoxidase antibody labeling of the cells in Figure 6b confirmed that the IL-10E1-MmGFP fusion protein was specifically localized in the nucleus after 10 min. In comparison, in cells injected with the nt-nls mY57/mY62-MmGFP fusion peptide, the peptide remained in the cytoplasmic compartment after 10 and 30 min of stimulation (Figure 6k and l, respectively) or even after 60 and 120 min of stimulation (data not shown). In attempts to semiquantify the process, at least 300 cells were injected with either IL-10E1-MmGFP fusion protein, nt-nls-MmGFP, nt-nls mC61-MmGFP, or ntnls mY57/mY62-MmGFP fusion peptides. Following exposure to ligand, the cells were fixed with À201C methanol and then examined by confocal microscopy. The transport of the fusion protein or peptide from the cytoplasm to the nucleus was semiquantified by counting 100 cells in B10 fields of view. In untreated or BSAtreated cells, all of the IL-10E1, nt-nls, nt-nls mC61 and nt-nls mY57/mY62 fusion proteins/peptides were located in the cytoplasmic compartment. Likewise, in cells exposed either to IL-10 plus IL-10R antibodies (1 : 200 dilution), IFNa, IL-4, or IL-6 (at 10 ng/ml), the three different fusion proteins/peptides remained in the cytoplasm (Table 1 ) (i.e. except for a very few cells). In comparison, IL-10 exhibited a dosage-dependent ability to stimulate the nuclear transport of the IL-10E1-MmGFP fusion protein and the nt-nls-MmGFP fusion peptide. In cells exposed to IL-10 at 5 ng/ml for 30 min, the percentage of cells exhibiting intense nuclear fluorescence was 71 and 68%, respectively. In cells exposed to IL-10 at 15 ng/ml for 30 min, 100% of the cells exhibited intense nuclear fluorescence with little or no detectable cytoplasmic labeling (Table 1 ). In contrast, in cells injected with the mutant nt-nls mY57/ mY62-MmGFP fusion peptide, the construct failed to (Table 1) .
Peptides containing phosphorylated Tyr
446
, or phosphorylated Tyr 476 groups completely block nt-nlsMmGFP translocation to the nucleus in IL-10-treated cells
The data in Table 2 showed that coinjection of the ntnls-MmGFP fusion protein with bovine serum albumin (BSA) did not block IL-10 signaling in 100% of the cells (i.e. in 100/100 cells) examined. However, coinjection experiments with the 12 amino-acid IL-10R peptides consisting of either phosphorylated Tyr 446 or phosphorylated Tyr 476 groups completely blocked nt-nlsMmGFP translocation to the nucleus in IL-10-treated cells (Table 2, , and Tyr 252/283 peptides. Following incubation of B4 h at 371C, cells were exposed to IL-10 (15 ng/ml) for 30 min at 371C and fixed in À201C methanol for confocal microscopy imaging. In all, 100 cells were examined in B10 fields of view to assess the percentage of cells exhibiting accumulation of the fusion protein in the nuclear compartment In all, 100 cells were examined in 10 fields of view to assess the percentage of cells exhibiting the accumulation of the fusion protein in the nuclear compartment. Note that only cells were counted where there was a definite localization of the fusion construct in either the cytoplasm or nucleus. There were a small percentage of cells (o5/100 cells) where both the cytoplasm and the nucleus appeared to contain fluorescent protein. BSA, bovine serum albumin IL-10 signaling via IL-10E1 is dependent on tyrosine phosphorylation ME Stearns et al 238 (230-P) peptide and the 250-262 (252/259-P) peptide) did not. The studies were extended to in vivo experiments utilizing a fusion protein between human IL-10E1 and a modified form of GFP. The initial experiments showed that the fusion construct was a valid live-cell marker for the behavior of endogenous IL-10E1 in human cells. Using this marker, we were able to confirm earlier observations (Liu et al., 1993) indicating that IL-10 triggers activation of IL-10E1 and transport from the cytoplasmic compartment to the nucleus. Confocal imaging revealed that IL-10E1 accumulates in the nucleus by 10-30 min and remains there for prolonged intervals (at least 4-6 h). Similar results were achieved with the truncated nt-nls and nt-nls mC61 IL-10E1 fragments, indicating that the LIM domain of the IL-10E1 might play a critical role in the signaling pathway. Note that the mutant mY57/mY62 peptide failed to migrate to the nucleus, suggesting that tyrosine phosphorylation of the IL-10E1 LIM domain groups was critical for IL-10R activation.
One Earlier studies by others of the IL-10R in white blood cell lines identified functionally important regions of the cytoplasmic domain of the murine IL-10R using deletion and substitution mutagenesis approaches (Weber-Nordt et al, 1996) . This approach showed that two tyrosine residues at positions 427 and 477 could each function in the IL-10 signal transduction process. Individual substitution of either Tyr 427 or Tyr 477 with phenylalanine led to the generation of a functionally inactive receptor (Weber-Nordt et al, 1996) . Cells bearing the IL-10R deletion mutant D402-559 failed to activate STAT1 signaling, although STAT3 and STAT5 were both activated upon ligand binding, presumably involving distinct receptor recruitment mechanisms. In addition, competition experiments with phosphotyrosine peptides indicated that STAT1 specifically binds either phosphorylated forms of Tyr 427 or Tyr 477 in a manner similar to that described here for IL-10E1 binding to Tyr 446 or Tyr 496 of the human IL-10R (WeberNordt et al, 1996) . Thus, the murine and human IL10Rs appear to act in a similar fashion to recruit and activate specific signal molecules.
Apparently, the IL-10Rs of murine and human possess distinct sequences and capabilities that may also be cell type and/or tumor specific. The human protein contains two conserved cytoplasmic domain tyrosine residues (Tyr 446 and Tyr
496
) that correspond to the two functionally important tyrosines identified in the cytoplasmic domain of the murine IL-10R (i.e. Tyr 427 and Tyr 477 ) . The amino-acid sequences are highly conserved adjacent to the tyrosine residues, but overall only a 60% identity is observed between human and murine sequences at the amino-acid level Weber-Nordt et al, 1996) .
At this juncture, we feel that a more complete characterization of the molecular basis for activation is warranted. One important issue not addressed in this study involves the identity and orientation of the key residues within the human IL-10R 'peptide motif' that mediate IL-10E1 attachment. In addition, it is important to examine whether the IL-10R in human prostate tumors also binds specific STAT proteins (i.e. Studies by other laboratories have previously implicated IL-10 and other cytokines in the regulation of TIMP-1 and MMP expression in a variety of white blood cell lines (Lacraz et al., 1993 (Lacraz et al., , 1995 . For example, studies examining the role of IL-6 on collagenase and TIMP-1 production in human fibroblasts, synoviocytes, chondrocytes, and macrophages (Lacraz et al., 1993) indicated that IL-6 does not stimulate collagenase production, but is a potent inducer of TIMP-1. In comparison, IL-4 and IFNg were found to inhibit collagenase expression, but not influence TIMP secretion (Lacraz et al., 1993) . Lacraz et al. (1995) further compared the effects of IL-10, IL-4, IL-2, IL-6, and INFg on MMP-9, interstitial collagenase, and TIMP-1 synthesis in human macrophages and monocytes. They reported that IL-10 and IL-4 inhibited the production of MMP-9. These data agree with the results reported by our group showing IL-10 controls TIMP-1 expression (Liu et al., 1993; Stearns et al., 1995) . Whether the signaling cascade involves IL-10E1 or specific STAT proteins is under investigation.
Abbreviations HPCA-10, human prostate cancer cells (derived from Gleason sum 10 tumor tissue); IL-10, interleukin 10; IL-10E1, interleukin 10 enhancer 1; nt-nls, n-terminal peptide of IL-10E1; IL-10R, interleukin 10 receptor; JAK, Janus kinase; TYK, tyrosine kinase; STATs, signal transducers and activators of transcription; SH2, Src homology 2; PAGE, polyacrylamide gel electrophoresis; EMSA, electrophoretic mobility shift assay; GFP, green fluorescent protein; TIMP-1, tissue inhibitor of matrix metalloproteinase-1.
